- Tytuł:
- Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
- Autorzy:
- Źródło:
- In The Lancet Neurology July 2022 21(7):608-619
Czasopismo naukowe